Health & biology · 2022
Tirzepatide
A dual GIP and GLP-1 agonist produced average weight loss of around 20 percent.
Eli Lilly's Mounjaro was approved for type 2 diabetes in 2022 and as Zepbound for obesity in 2023. It set a new bar for drug-based weight loss.